PERCHERON THERAPEUTICS LIMITED - Announcements

Market Cap $68.51M Add to my watchlist

Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

PER	WHO selects proposed INN for ATL1102		06/05/24	99.66KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	421.52KB	Share
PER	Change in substantial holding		26/04/24	224.86KB	Share
PER	ATL1102 Clinical Trial Update		02/04/24	254.91KB	Share
PER	ATL1102 Data presented at MDA Annual Conference		04/03/24	2.1MB	Share
PER	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/24	9.38MB	Share
PER	Percheron Therapeutics Limited Corporate Presentation		26/02/24	1.7MB	Share
PER	Change of Registered Office and Principal Place of Business		21/02/24	176.34KB	Share
PER	Receipt of R&D Tax incentive payment	PRICE SENSITIVE	12/02/24	174.65KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	325.23KB	Share
PER	ATL1102 DMD Phase IIA Final Data Published		29/01/24	172.45KB	Share
PER	Change of Company Name		02/01/24	77.6KB	Share
PER	Notification of cessation of securities - ANP		22/12/23	22.08KB	Share
PER	Change of Director's Interest Notice (CG,JG)		30/11/23	287.5KB	Share
PER	Notification regarding unquoted securities - ANP		30/11/23	32.6KB	Share
PER	Antisense completes Unmarketable Parcels facility		27/11/23	74.97KB	Share
PER	Proposed issue of securities - ANP		24/11/23	31.8KB	Share
PER	Change of Director's Interest Notice (JG)		21/11/23	245.86KB	Share
PER	Results of Annual General Meeting		15/11/23	288.75KB	Share
PER	Annual General Meeting Presentation		15/11/23	1.48MB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	1.43MB	Share
PER	Change in substantial holding		17/10/23	229.38KB	Share
PER	Notice of Annual General Meeting/Proxy Form		17/10/23	777.87KB	Share
PER	Antisense to participate in upcoming investor conferences		16/10/23	93.82KB	Share
PER	Antisense launches Unmarketable Parcels facility		09/10/23	530.34KB	Share
PER	Change of Director's Interest Notice GP		02/10/23	239.17KB	Share
PER	Publication of final Long COVID data for ATL1102		28/09/23	144.18KB	Share
PER	Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy	PRICE SENSITIVE	26/09/23	125.86KB	Share
PER	Antisense Therapeutics Corporate Presentation		28/08/23	1.49MB	Share
PER	Appendix 4G		25/08/23	245.69KB	Share
PER	Corporate Governance Statement		25/08/23	253.16KB	Share
PER	Appendix 4E and Annual Report	PRICE SENSITIVE	25/08/23	2.88MB	Share
PER	Change of Director's Interest Notice (CG,JG)		22/08/23	320.42KB	Share
PER	Application for quotation of securities - ANP		22/08/23	24.58KB	Share
PER	Antisense Share Purchase Plan (SPP) Raises $3.26 Million	PRICE SENSITIVE	21/08/23	90.47KB	Share
PER	Commencement of Chief Executive Officer		07/08/23	87.37KB	Share
PER	Share Purchase Plan (SPP) Offer Booklet	PRICE SENSITIVE	28/07/23	583.89KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	754.54KB	Share
PER	Positive new DMD Combination Therapy Data in mdx mice	PRICE SENSITIVE	26/07/23	134.61KB	Share
PER	Becoming a substantial holder		25/07/23	148.5KB	Share
PER	Notice under Section 708A		24/07/23	172.87KB	Share
PER	Application for quotation of securities - ANP		24/07/23	24.64KB	Share
PER	Proposed issue of securities - ANP		20/07/23	27.74KB	Share
PER	Intention to launch Share Purchase Plan	PRICE SENSITIVE	20/07/23	244.07KB	Share
PER	Quarterly Activities Report	PRICE SENSITIVE	20/07/23	244.07KB	Share
PER	Proposed issue of securities - ANP		18/07/23	25.38KB	Share
PER	Institutional Placement and proposed Share Purchase Plan SPP	PRICE SENSITIVE	18/07/23	125.38KB	Share
PER	Trading Halt	PRICE SENSITIVE	14/07/23	546.51KB	Share
PER	MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK	PRICE SENSITIVE	27/06/23	116.52KB	Share
PER	First Patient Dosed in ATL1102 Phase IIb DMD Trial	PRICE SENSITIVE	08/06/23	99.54KB	Share
PER	Shareholder Newsletter		06/06/23	148.86KB	Share
PER	Final Director's Interest Notice		12/05/23	265.24KB	Share
PER	Change of Director's Interest Notice (JG)		11/05/23	291.54KB	Share
PER	Initial Director's Interest Notice		09/05/23	217.73KB	Share
PER	Chief Executive Officer and Managing Director Appointment	PRICE SENSITIVE	08/05/23	168.73KB	Share
PER	PIIb DMD trial approved in Bulgaria- UK, Australia advancing	PRICE SENSITIVE	26/04/23	106.71KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	17/04/23	649.93KB	Share
PER	Removal from Official List		17/03/23	87.01KB	Share
PER	Dosing commenced in the ATL1102 toxicology study	PRICE SENSITIVE	14/03/23	137.81KB	Share
PER	Suspension of Notes from Official Quotation	PRICE SENSITIVE	07/03/23	91.29KB	Share
PER	Notice under Section 708A		07/03/23	131.36KB	Share
PER	Application for quotation of securities - ANP		07/03/23	25.1KB	Share
PER	Proposed issue of securities - ANP		06/03/23	24.49KB	Share
PER	Letter to Shareholders		01/03/23	128.29KB	Share
PER	Receipt of R&D Tax Incentive Payment	PRICE SENSITIVE	23/02/23	75.04KB	Share
PER	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/23	1.23MB	Share
PER	Presentation at International Conference on DMD		17/02/23	99.93KB	Share
PER	First approval for ATL1102 Phase IIb DMD clinical trial	PRICE SENSITIVE	14/02/23	99.78KB	Share
PER	Limb Girdle Muscular Dystrophy R2 animal study commenced	PRICE SENSITIVE	13/02/23	106.94KB	Share
PER	Positive outcomes in DMD combination therapy animal study	PRICE SENSITIVE	01/02/23	317.87KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/23	294.12KB	Share
PER	Notification regarding unquoted securities - ANP		21/12/22	32.59KB	Share
PER	Phase IIb DMD CTA submitted for trial conduct in Europe		19/12/22	84.83KB	Share
PER	Application for quotation of securities - ANP		23/11/22	24.99KB	Share
PER	Final Director's Interest Notice (GWP)		22/11/22	179.18KB	Share
PER	Results of Annual General Meeting		17/11/22	213.22KB	Share
PER	AGM Presentation		17/11/22	1.28MB	Share
PER	Antisense Therapeutics CEO announces retirement	PRICE SENSITIVE	15/11/22	79.09KB	Share
PER	ATL1102 tox study to support clinical program in the US	PRICE SENSITIVE	14/11/22	126.07KB	Share
PER	Change of Registry Address		31/10/22	77.61KB	Share
PER	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/22	413.77KB	Share
PER	Appendix 4G		19/10/22	275.72KB	Share
PER	Corporate Governance Statement		19/10/22	175.88KB	Share
PER	Annual Report		19/10/22	5.41MB	Share
PER	Notice of Annual General Meeting		19/10/22	1.46MB	Share
PER	Non-Executive Director Retirement		14/10/22	112.51KB	Share
PER	Receipt of further R&D Tax Incentive Payment		14/10/22	76.15KB	Share
PER	Change of Director's Interest Notice (GP)		07/10/22	284.12KB	Share
PER	Company Appointment Chief Commercial Officer		05/10/22	159.86KB	Share
PER	Change of Director's Interest Notice (GP)		04/10/22	239.41KB	Share
PER	Change of Director's Interest Notice (GP)		29/09/22	238.75KB	Share
PER	Dosing commenced in DMD combination therapy study	PRICE SENSITIVE	12/09/22	197.94KB	Share
PER	ATL1102 Revised Clinical Development Plans Presentation	PRICE SENSITIVE	07/09/22	551.07KB	Share
PER	ATL1102 Revised Plans accelerate reporting of unblinded data	PRICE SENSITIVE	07/09/22	137.83KB	Share
PER	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	31/08/22	1.4MB	Share
PER	Ceasing to be a substantial holder		22/08/22	125.46KB	Share
PER	Reinstatement to Official Quotation	PRICE SENSITIVE	19/08/22	86.41KB	Share
PER	Response to ASX Query	PRICE SENSITIVE	19/08/22	235.64KB	Share
PER	Long Covid-19 Collaboration Outcomes Presentation	PRICE SENSITIVE	19/08/22	1.62MB	Share
PER	Long COVID study identifies diagnostic & therapeutic targets	PRICE SENSITIVE	19/08/22	183.69KB	Share

PER WHO selects proposed INN for ATL1102
06/05/24		99.66KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	421.52KB	Share
PER Change in substantial holding
26/04/24		224.86KB	Share
PER ATL1102 Clinical Trial Update
02/04/24		254.91KB	Share
PER ATL1102 Data presented at MDA Annual Conference
04/03/24		2.1MB	Share
PER Half Yearly Report and Accounts
28/02/24	PRICE SENSITIVE	9.38MB	Share
PER Percheron Therapeutics Limited Corporate Presentation
26/02/24		1.7MB	Share
PER Change of Registered Office and Principal Place of Business
21/02/24		176.34KB	Share
PER Receipt of R&D Tax incentive payment
12/02/24	PRICE SENSITIVE	174.65KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	325.23KB	Share
PER ATL1102 DMD Phase IIA Final Data Published
29/01/24		172.45KB	Share
PER Change of Company Name
02/01/24		77.6KB	Share
PER Notification of cessation of securities - ANP
22/12/23		22.08KB	Share
PER Change of Director's Interest Notice (CG,JG)
30/11/23		287.5KB	Share
PER Notification regarding unquoted securities - ANP
30/11/23		32.6KB	Share
PER Antisense completes Unmarketable Parcels facility
27/11/23		74.97KB	Share
PER Proposed issue of securities - ANP
24/11/23		31.8KB	Share
PER Change of Director's Interest Notice (JG)
21/11/23		245.86KB	Share
PER Results of Annual General Meeting
15/11/23		288.75KB	Share
PER Annual General Meeting Presentation
15/11/23		1.48MB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	1.43MB	Share
PER Change in substantial holding
17/10/23		229.38KB	Share
PER Notice of Annual General Meeting/Proxy Form
17/10/23		777.87KB	Share
PER Antisense to participate in upcoming investor conferences
16/10/23		93.82KB	Share
PER Antisense launches Unmarketable Parcels facility
09/10/23		530.34KB	Share
PER Change of Director's Interest Notice GP
02/10/23		239.17KB	Share
PER Publication of final Long COVID data for ATL1102
28/09/23		144.18KB	Share
PER Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
26/09/23	PRICE SENSITIVE	125.86KB	Share
PER Antisense Therapeutics Corporate Presentation
28/08/23		1.49MB	Share
PER Appendix 4G
25/08/23		245.69KB	Share
PER Corporate Governance Statement
25/08/23		253.16KB	Share
PER Appendix 4E and Annual Report
25/08/23	PRICE SENSITIVE	2.88MB	Share
PER Change of Director's Interest Notice (CG,JG)
22/08/23		320.42KB	Share
PER Application for quotation of securities - ANP
22/08/23		24.58KB	Share
PER Antisense Share Purchase Plan (SPP) Raises $3.26 Million
21/08/23	PRICE SENSITIVE	90.47KB	Share
PER Commencement of Chief Executive Officer
07/08/23		87.37KB	Share
PER Share Purchase Plan (SPP) Offer Booklet
28/07/23	PRICE SENSITIVE	583.89KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	754.54KB	Share
PER Positive new DMD Combination Therapy Data in mdx mice
26/07/23	PRICE SENSITIVE	134.61KB	Share
PER Becoming a substantial holder
25/07/23		148.5KB	Share
PER Notice under Section 708A
24/07/23		172.87KB	Share
PER Application for quotation of securities - ANP
24/07/23		24.64KB	Share
PER Proposed issue of securities - ANP
20/07/23		27.74KB	Share
PER Intention to launch Share Purchase Plan
20/07/23	PRICE SENSITIVE	244.07KB	Share
PER Quarterly Activities Report
20/07/23	PRICE SENSITIVE	244.07KB	Share
PER Proposed issue of securities - ANP
18/07/23		25.38KB	Share
PER Institutional Placement and proposed Share Purchase Plan SPP
18/07/23	PRICE SENSITIVE	125.38KB	Share
PER Trading Halt
14/07/23	PRICE SENSITIVE	546.51KB	Share
PER MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
27/06/23	PRICE SENSITIVE	116.52KB	Share
PER First Patient Dosed in ATL1102 Phase IIb DMD Trial
08/06/23	PRICE SENSITIVE	99.54KB	Share
PER Shareholder Newsletter
06/06/23		148.86KB	Share
PER Final Director's Interest Notice
12/05/23		265.24KB	Share
PER Change of Director's Interest Notice (JG)
11/05/23		291.54KB	Share
PER Initial Director's Interest Notice
09/05/23		217.73KB	Share
PER Chief Executive Officer and Managing Director Appointment
08/05/23	PRICE SENSITIVE	168.73KB	Share
PER PIIb DMD trial approved in Bulgaria- UK, Australia advancing
26/04/23	PRICE SENSITIVE	106.71KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
17/04/23	PRICE SENSITIVE	649.93KB	Share
PER Removal from Official List
17/03/23		87.01KB	Share
PER Dosing commenced in the ATL1102 toxicology study
14/03/23	PRICE SENSITIVE	137.81KB	Share
PER Suspension of Notes from Official Quotation
07/03/23	PRICE SENSITIVE	91.29KB	Share
PER Notice under Section 708A
07/03/23		131.36KB	Share
PER Application for quotation of securities - ANP
07/03/23		25.1KB	Share
PER Proposed issue of securities - ANP
06/03/23		24.49KB	Share
PER Letter to Shareholders
01/03/23		128.29KB	Share
PER Receipt of R&D Tax Incentive Payment
23/02/23	PRICE SENSITIVE	75.04KB	Share
PER Half Yearly Report and Accounts
22/02/23	PRICE SENSITIVE	1.23MB	Share
PER Presentation at International Conference on DMD
17/02/23		99.93KB	Share
PER First approval for ATL1102 Phase IIb DMD clinical trial
14/02/23	PRICE SENSITIVE	99.78KB	Share
PER Limb Girdle Muscular Dystrophy R2 animal study commenced
13/02/23	PRICE SENSITIVE	106.94KB	Share
PER Positive outcomes in DMD combination therapy animal study
01/02/23	PRICE SENSITIVE	317.87KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
25/01/23	PRICE SENSITIVE	294.12KB	Share
PER Notification regarding unquoted securities - ANP
21/12/22		32.59KB	Share
PER Phase IIb DMD CTA submitted for trial conduct in Europe
19/12/22		84.83KB	Share
PER Application for quotation of securities - ANP
23/11/22		24.99KB	Share
PER Final Director's Interest Notice (GWP)
22/11/22		179.18KB	Share
PER Results of Annual General Meeting
17/11/22		213.22KB	Share
PER AGM Presentation
17/11/22		1.28MB	Share
PER Antisense Therapeutics CEO announces retirement
15/11/22	PRICE SENSITIVE	79.09KB	Share
PER ATL1102 tox study to support clinical program in the US
14/11/22	PRICE SENSITIVE	126.07KB	Share
PER Change of Registry Address
31/10/22		77.61KB	Share
PER Quarterly Activities/Appendix 4C Cash Flow Report
26/10/22	PRICE SENSITIVE	413.77KB	Share
PER Appendix 4G
19/10/22		275.72KB	Share
PER Corporate Governance Statement
19/10/22		175.88KB	Share
PER Annual Report
19/10/22		5.41MB	Share
PER Notice of Annual General Meeting
19/10/22		1.46MB	Share
PER Non-Executive Director Retirement
14/10/22		112.51KB	Share
PER Receipt of further R&D Tax Incentive Payment
14/10/22		76.15KB	Share
PER Change of Director's Interest Notice (GP)
07/10/22		284.12KB	Share
PER Company Appointment Chief Commercial Officer
05/10/22		159.86KB	Share
PER Change of Director's Interest Notice (GP)
04/10/22		239.41KB	Share
PER Change of Director's Interest Notice (GP)
29/09/22		238.75KB	Share
PER Dosing commenced in DMD combination therapy study
12/09/22	PRICE SENSITIVE	197.94KB	Share
PER ATL1102 Revised Clinical Development Plans Presentation
07/09/22	PRICE SENSITIVE	551.07KB	Share
PER ATL1102 Revised Plans accelerate reporting of unblinded data
07/09/22	PRICE SENSITIVE	137.83KB	Share
PER Appendix 4E and Full Year Statutory Accounts
31/08/22	PRICE SENSITIVE	1.4MB	Share
PER Ceasing to be a substantial holder
22/08/22		125.46KB	Share
PER Reinstatement to Official Quotation
19/08/22	PRICE SENSITIVE	86.41KB	Share
PER Response to ASX Query
19/08/22	PRICE SENSITIVE	235.64KB	Share
PER Long Covid-19 Collaboration Outcomes Presentation
19/08/22	PRICE SENSITIVE	1.62MB	Share
PER Long COVID study identifies diagnostic & therapeutic targets
19/08/22	PRICE SENSITIVE	183.69KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 7.6¢		Change -0.004(5.00%)		Mkt cap ! $68.51M

Open	High	Low	Value	Volume
8.0¢	8.0¢	7.6¢	$201.6K	2.545M

Buyers (Bids)

No.	Vol.	Price($)
2	146314	7.6¢

Sellers (Offers)

Price($)	Vol.	No.
8.3¢	106165	2

View Market Depth

No.	Vol.	Price($)
2	146314	0.076
1	10000	0.075
1	12990	0.073
3	472000	0.072
1	20000	0.071

Price($)	Vol.	No.
0.083	106165	2
0.085	250000	2
0.086	6000	1
0.087	25001	1
0.088	100000	1

Last trade - 16.10pm 09/05/2024 (20 minute delay)


Last 7.7¢		Change -0.004 ( 3.75 %)
Open	High	Low	Volume
7.9¢	8.0¢	7.7¢	79316
Last updated 15.57pm 09/05/2024 ?

PER (ASX) Chart

PERCHERON THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories